Plasma exchange in systemic lupus erythematosus.

Area of Science:

• Immunology
• Rheumatology
• Nephrology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune complex deposition.
• Active SLE often requires intensive treatment when standard therapies are insufficient.
• Plasma exchange (PE) is a therapeutic apheresis technique that removes plasma components.

Purpose of the Study:

• To evaluate the efficacy of plasma exchange as an adjunctive therapy in patients with active systemic lupus erythematosus (SLE).
• To assess the impact of PE on immune complex levels and anti-DNA antibodies in SLE patients.
• To determine the potential benefits of PE in conjunction with other therapeutic strategies.

Main Methods:

• Plasma exchange (PE) was administered to 8 out of 14 patients diagnosed with systemic lupus erythematosus (SLE).
• PE was implemented as supplementary treatment for patients experiencing active disease who showed inadequate response to conventional therapies.
• Monitoring of immune complex serum levels and anti-DNA antibodies was conducted throughout the treatment period.

Main Results:

• Patients undergoing PE demonstrated significant clinical improvement compared to those not receiving it.
• Immune complex serum levels decreased rapidly in patients treated with PE.
• Anti-DNA antibody levels showed a slower but consistent decline following PE therapy.

Conclusions:

• Plasma exchange (PE) can be a beneficial therapeutic option for managing active systemic lupus erythematosus (SLE), particularly in cases refractory to conventional treatment.
• The rapid reduction in immune complexes suggests PE's effectiveness in clearing pathogenic factors.
• Combining PE with medications that inhibit antibody production may enhance treatment outcomes and prevent disease relapse.